- Home
- ATHA vs AEI Comparison
ATHA vs AEI Comparison
Compare ATHA & AEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- AEI
- Stock Information
- Founded
- ATHA 2011
- AEI 2014
- Country
- ATHA United States
- AEI United States
- Employees
- ATHA N/A
- AEI N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- AEI Building operators
- Sector
- ATHA Health Care
- AEI Real Estate
- Exchange
- ATHA Nasdaq
- AEI Nasdaq
- Market Cap
- ATHA 14.8M
- AEI 13.6M
- IPO Year
- ATHA 2020
- AEI N/A
- Fundamental
- Price
- ATHA $0.40
- AEI $1.30
- Analyst Decision
- ATHA Hold
- AEI
- Analyst Count
- ATHA 3
- AEI 0
- Target Price
- ATHA $0.50
- AEI N/A
- AVG Volume (30 Days)
- ATHA 133.3K
- AEI 52.6K
- Earning Date
- ATHA 08-07-2025
- AEI 08-14-2025
- Dividend Yield
- ATHA N/A
- AEI N/A
- EPS Growth
- ATHA N/A
- AEI N/A
- EPS
- ATHA N/A
- AEI N/A
- Revenue
- ATHA N/A
- AEI $16,069,911.00
- Revenue This Year
- ATHA N/A
- AEI N/A
- Revenue Next Year
- ATHA N/A
- AEI N/A
- P/E Ratio
- ATHA N/A
- AEI N/A
- Revenue Growth
- ATHA N/A
- AEI 74.28
- 52 Week Low
- ATHA $0.22
- AEI $0.70
- 52 Week High
- ATHA $3.51
- AEI $2.61
- Technical
- Relative Strength Index (RSI)
- ATHA 53.29
- AEI 56.52
- Support Level
- ATHA $0.38
- AEI $1.16
- Resistance Level
- ATHA $0.41
- AEI $1.36
- Average True Range (ATR)
- ATHA 0.02
- AEI 0.09
- MACD
- ATHA -0.00
- AEI 0.00
- Stochastic Oscillator
- ATHA 71.70
- AEI 57.38
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About AEI Alset Inc. (TX)
Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.